ABUS vs SRE · P/E 5.4, rev $6.2M vs P/E 31, rev $13.70B
Arbutus Biopharma Corp (ABUS) versus Sempra Energy (SRE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Sempra Energy (SRE) is a utilities - diversified company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported SRE revenue for 2025-12-31 was $13.70B. Net income was $1.84B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. SRE currently screens at market cap $59.76B and trailing P/E 31.1.
Not investment advice. Open the ABUS and SRE stock pages for the full models.
Not investment advice.